Managing patients with 'wet' overactive bladder: Results of pooled studies show efficacy of darifenacin as measured by 'Dry Days'

UroToday International Journal

Volumn 3, Issue 6, 2010, Pages

  Newman, Diane ^a   Aronstein, William S ^b   Seifu, Yodit ^c   Larson Peters, Andrea ^d   Mongay, Lidia ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CTI Clinical Trial and Consulting Services   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Antimuscarinic agents; Darifenacin; Overactive bladder; Urinary incontinence

Indexed keywords

EID: 78649975351     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2010.12.11     Document Type: Article

References (27)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336.
2. Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
3. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580-S590.
4. Irwin DE, Milsom I, Kopp Z, Abrams P; EPIC Study Group. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029-1039.
5. Hannestad YS, Rortveit G, Hunskaar S. Help-seeking and associated factors in female urinary incontinence. The Norwegian EPINCONT Study. Epidemiology of Incontinence in the County of Nord-Trondelag. Scand J Prim Health Care. 2002;20:102-107.
6. Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump R, Obenchain R. Factors associated with women's decisions to seek treatment for urinary incontinence. J Womens Health (Larchmt). 2003;12(7):687-698.
7. Fultz NH, Herzog AR. Self-reported social and emotional impact of urinary incontinence. J Am Geriatr Soc. 2001;49(7):892-899.
8. Subak LL, Brown JS, Kraus SR, et al; Diagnostic Aspects of Incontinence Study Group. The "costs" of urinary incontinence for women. Obstet Gynecol. 2006;107(4):908- 916.
9. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46-53.
10. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63(8):1177-1191.
11. Chapple CR, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95(7):993-1001.
12. Abrams P, Kelleher C, Huels J, Quebe-Fehling E, Omar MA, Steel M. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int. 2008;102(2):208-213.
13. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079-1086.
14. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45(4):420-429, discussion 429.
15. Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005;95(4):580-586.
16. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006;98(5):1025-1032.
17. Novartis Pharmaceuticals Corp. Enablex® (darifenacin extended-release tablets). US Prescribing Information. http://www pharmausnovartiscom/product/pi/pdf/enablexpdf. 2008;T2008-60 (Accessed October 21, 2010).
18. Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102(9):1128- 1132.
19. Chapple CR. Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. Expert Opin Pharmacother. 2006;7(17):2421-2434.
20. Diokno AC, Appell RA, Sand PK, et al; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687-695.
21. Basra R, Kelleher C. A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag. 2008;4(1):117-128.
22. Wein AJ, Khullar V, Wang JT, Guan Z. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int. 2007;99(2):360-363.
23. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388-1395.
24. Dwyer P, Kelleher C, Young J, et al. Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study. Neurourol Urodyn. 2008;27(6):540-547.
25. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71(5):839-843.
26. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14-24.
27. Foote J, Glavind K, Kralidis G, Wyndaele J-J. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48(3):471-477.